Immunotherapy – not all approaches work the same
- This topic has 3 replies, 3 voices, and was last updated 10 years ago by
.
-
Posts
-
Judy….. Most major centers are involved in these studies. You might want to start with the treating physician, as he/she may be able to lead you to a center closest for participation. I believe that once approved for a different cancer, physicians will then use the “off label” and the pd-1 and anti pd-L1 pembrolizumab (lambrolizumab) drug are under investigation and are expected to be released by the end of this year.
From what I have learned the NIH is overrun with request, but Melinda’s study is recruiting:
http://clinicaltrials.gov/ct2/results?term=NCT01174121&Search=SearchThe newest in the making are the n-of-1 trials (single patient trials) part of personalized medicine. But, I have little information on this.
Hugs,
MarionJust wondering…What are the hospitals/who are the physicians and immunogists leading the exploration of immunotherapy for cholangiocarcinoma? What are the opportunities for the inclusion of cholangio if FDA approval is received for treatment of a different cancer?
Thanks Marion, much excitement surrounding Immunotherapy and let’s hope that much of it will be carried through to CC.
Hugs,
Gavin
according to a Twitter Chat and reported by The Augusta Chronicle:
http://chronicle.augusta.com/news/health/2014-06-18/immunotherapy-promising-cancer
- The forum ‘New Developments’ is closed to new topics and replies.